A study evaluating the response of 185 patients to discontinuation of anti-PD-1 agents in the absence of progression or toxicity showed that the risk of disease progression after discontinuation was higher in patients whose initial objective tumor response was SD (50%) compared to those who initially experienced a complete response (CR) to treatment (14%). This evidence concerns the gene PDCD1 and neoplasm.